U.S. Stock Market Movement: SELLAS Life Sciences Plummets on November 20 Following Discounted Underwritten Offering, Share Dilution, and Broad Market Decline
Bitget异动解读2026/11/20 15:35SELLAS Life Sciences November 20 Sharp Decline Analysis
Keywords: discounted underwritten offering, equity dilution, overall market downturn
1. On November 18, SELLAS announced a fully underwritten public offering of 11,538,462 shares of common stock at a price of $13.00 per share, raising a total of approximately $150 million. The offering price represents a discount of about 28% compared to Wednesday’s closing price, significantly below the previous level of around $19. Concerns over dilution put pressure on the stock price, which fell nearly 18% in pre-market trading that day and continued trending lower after the open.
2. On November 17, after the company released positive top-line data from the phase 3 REGAL trial, the share price surged about 156% in a single day. The price gap created by this discounted offering after such a rapid run-up has become a major market focus.
3. On November 20, the overall US stock market declined, with Nasdaq 100 index futures down 1.8%, S&P 500 index futures down nearly 1%, and the Nasdaq Composite Index dropping 1.70% in the previous session. Sector movements and the broader market environment weighed on individual stocks.
(Disclaimer: This content is summarized and generated from publicly available information using AI technology. It is provided for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CoreWeave drops 8.1% intraday, bearish options surge 53% with 1,305 contracts traded